Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Enanta Pharmaceuticals announced that the FDA has accepted its New Drug Application (NDA) for priority review for AbbVie’s all-oral, interferon-free regimen in the treatment of adults with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.
The investigational regimen consists of a fixed-dose combination of boosted protease inhibitor ABT-450/ritonavir (150mg/100mg), NS5A inhibitor ombitasvir (ABT-267) 25mg, and non-nucleoside polymerase inhibitor dasabuvir (ABT-333) 250mg with or without ribavirin.
RELATED: NDA Submitted for All-Oral, Interferon-Free Hepatitis C Regimen
The NDA is supported by data from a large clinical program being conducted by AbbVie, including six Phase 3 studies of more than 2,300 GT1 patients. Previously the regimen was granted Breakthrough Therapy designation by the FDA in May 2013.
For more information call (617) 607-0800 or visit Enanta.com.
